Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Amsacrine (AMSA) 是一种抗肿瘤剂,可以嵌入到肿瘤细胞的 DNA 中。它还表达拓扑异构酶抑制剂活性,特异性抑制拓扑异构酶 II。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 139 | 现货 | ||
5 mg | ¥ 297 | 现货 | ||
10 mg | ¥ 497 | 现货 | ||
25 mg | ¥ 693 | 现货 | ||
50 mg | ¥ 897 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 327 | 现货 |
产品描述 | Amsacrine (AMSA) (mAMSA) an antineoplastic agent which can intercalate into the DNA of tumor cells. Amsacrine also expresses topoisomerase inhibitor activity, specifically inhibiting topoisomerase II. |
体外活性 | Amsacrine blocks HERG currents in HEK 293 cells and Xenopus oocytes in a concentration-dependent manner, with IC50 values of 209.4 nm and 2.0 μM, respectively. Amsacrine causes a negative shift in the voltage dependence of both activation (?7.6 mV) and inactivation (?7.6 mV). HERG current block by amsacrine is not frequency dependent[1]. In vitro studies of normal human lymphocytes with various concentrations of m-AMSA, show both increased levels of chromosomal aberrations, ranging from 8% to 100%, and increase SCEs, ranging from 1.5 times the normal at the lowest concentration studied (0.005 μg/mL) to 12 times the normal (0.25 μg/mL)[3]. Amsacrine-induced apoptosis of U937 cells is characterized by caspase-9 and caspase-3 activation, increased intracellular Ca2+ concentration, mitochondrial depolarization, and MCL1 down-regulation. Amsacrine induces MCL1 down-regulation by decreasing its stability. Further, amsacrine-treated U937 cells show AKT degradation and Ca2+-mediated ERK inactivation[4]. |
体内活性 | In animals treated with different doses of amsacrine (0.5-12 mg/kg), the frequencies of micronucleated polychromatic erythrocytes increase significantly after treatment with 9 and 12 mg/kg. Furthermore, the present study demonstrates for the first time that amsacrine has high incidences of clastogenicity and low incidences of aneugenicity whereas nocodazole has high incidences of aneugenicity and low incidences of clastogenicity during mitotic phases in vivo[2]. |
别名 | AMSA, m-AMSA, 安吖啶, CI-880, acridinyl anisidide |
分子量 | 393.46 |
分子式 | C21H19N3O3S |
CAS No. | 51264-14-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (127.08 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5416 mL | 12.7078 mL | 25.4155 mL | 63.5389 mL |
5 mM | 0.5083 mL | 2.5416 mL | 5.0831 mL | 12.7078 mL | |
10 mM | 0.2542 mL | 1.2708 mL | 2.5416 mL | 6.3539 mL | |
20 mM | 0.1271 mL | 0.6354 mL | 1.2708 mL | 3.1769 mL | |
50 mM | 0.0508 mL | 0.2542 mL | 0.5083 mL | 1.2708 mL | |
100 mM | 0.0254 mL | 0.1271 mL | 0.2542 mL | 0.6354 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Amsacrine 51264-14-3 Autophagy DNA Damage/DNA Repair Membrane transporter/Ion channel Potassium Channel Topoisomerase AMSA m-AMSA 安吖啶 Inhibitor CI880 CI-880 acridinyl anisidide inhibit CI 880 inhibitor